A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorMerck Sharp & Dohme LLC
About this trial
Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI).
The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.
Eligibility criteria
Qualifiers
Has a diagnosis of untreated latent tuberculosis infection (LTBI)
Has no symptoms of active tuberculosis (TB)
Has never received treatment for TB or LTBI
Other than having LTBI, is in good health
Disqualifiers
Has a diagnosis of LTBI made in the context of an outbreak/contact-tracing investigation
Has a current or anticipated immunocompromised state
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
Has a history of cancer (malignancy)
Trial design
Treatments tested in this trial
- MK-8527
- Rifampin
Treatment groups
14 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov